Understanding Glycogen Storage Disease Type III (Cori/Forbes Disease)
At a Glance
Glycogen Storage Disease Type III (Cori/Forbes disease) is a genetic condition where the body cannot properly break down stored energy. It is managed with a specialized high-protein diet, frequent meals, and complex carbs like cornstarch to prevent low blood sugar and protect muscles.
Receiving a diagnosis of Glycogen Storage Disease Type III (GSD III), also known as Cori disease or Forbes disease, can feel overwhelming. It is natural to feel a mix of shock, fear, or even relief at finally having an answer for certain symptoms [1]. While this is a lifelong condition that requires careful management, it is important to know that with modern dietary strategies and regular medical follow-up, many people with GSD III lead full and active lives [2][3].
This guide is designed to help you understand your diagnosis and navigate your care. You can explore the following sections for more detailed information:
GSD III Subtypes and Symptoms Over Time
Learn the differences between GSD IIIa and IIIb. Understand how symptoms like an enlarged liver, hypoglycemia, and muscle weakness progress over a lifespan.
Diagnosing GSD III and Understanding Your Results
Learn how Glycogen Storage Disease Type III (GSD III) is diagnosed. Understand AGL genetic test results, zygosity, CK levels, and look-alike conditions.
Treatment and Daily Management for GSD III
Learn about Glycogen Storage Disease Type III (GSD III) treatment. Understand how uncooked cornstarch, high-protein diets, and CGMs help manage daily symptoms.
Building Your Care Team and Lifelong Surveillance
Learn how to build your GSD III care team and understand lifelong surveillance. Discover recommended tests for liver, heart, and muscle health over time.
The Biology of GSD III
To understand GSD III, it helps to think of the body’s energy system as a library. Your body stores sugar (glucose) in the form of glycogen, which is like a large, branched book of energy stored in the liver and muscles. When you need energy between meals, your body “checks out” these books and breaks them down.
In GSD III, a mutation in the AGL gene means the body lacks a specific tool called the glycogen debranching enzyme (GDE) [4][5]. This enzyme is responsible for “unzipping” the branches of the glycogen molecule so it can be turned back into sugar. Without it, the body can only use the very outer tips of the glycogen branches [4]. The rest of the glycogen becomes “stuck” and accumulates in the cells of the liver, heart, and skeletal muscles, which can cause these organs to enlarge or weaken over time [5][6].
Inheritance and Genetics
GSD III is an autosomal recessive genetic condition [4]. This means:
- Both parents are carriers: Each parent carries one mutated copy of the AGL gene and one healthy copy. Carriers typically show no symptoms [7].
- The “Random Draw”: For each pregnancy, there is a 25% chance the child will inherit two mutated genes (one from each parent) and have GSD III [7].
- Family Planning: If you are an adult with GSD III planning to have children, your partner can undergo genetic testing to see if they are a carrier, which will help determine the risk to your future children [8].
- It is not your fault: Genetic mutations are a natural part of biology and are not caused by anything a parent did or didn’t do before or during pregnancy.
Stabilizing Facts for Families
While GSD III is complex, several key facts can provide stability as you navigate the early days of diagnosis:
- Hypoglycemia is Manageable: The primary immediate concern is often hypoglycemia (low blood sugar). This is highly manageable through consistent intake of complex carbohydrates, such as uncooked cornstarch, and frequent meals [9].
- The Liver Can Recover: In many children, the liver enlargement (hepatomegaly) and elevated liver enzymes seen at diagnosis can improve or stabilize with proper metabolic control [10].
- Protein is a Powerhouse: Current medical consensus emphasizes a high-protein diet to provide an alternative fuel source for the muscles and heart, which can help prevent long-term weakness [11][12]. Your metabolic dietitian will calculate a specific high-protein target tailored to your age, weight, and lab results.
- Technology is an Ally: Tools like Continuous Glucose Monitors (CGM), which use a small sensor to track blood sugar levels in real-time, have revolutionized care by providing peace of mind and reducing the need for constant finger-stick tests [2].
Common Misunderstandings
Clearing up misconceptions can help you focus on the most effective care:
- Misconception: “It’s just a childhood liver disease.” While liver symptoms are prominent in childhood, GSD III is a multisystem condition that requires lifelong attention to muscle and heart health [1][13].
- Misconception: “Symptoms always go away after puberty.” While some liver markers may improve during the teenage years, the risk of muscle weakness or liver issues remains. Regular checkups with a specialist are necessary throughout adulthood [10][14].
- Misconception: “Dietary restrictions are the same for all GSDs.” Unlike GSD I, where protein is less emphasized, people with GSD III specifically benefit from high-protein intake to protect their muscles [11].
A Multidisciplinary Approach
Because GSD III affects multiple parts of the body, care is typically coordinated by a team of specialists, including a metabolic geneticist, a specialized dietitian, a cardiologist (to monitor the heart), and sometimes a neurologist or physical therapist (to monitor muscle strength) [1][15]. Routine monitoring through blood work and imaging (like ultrasounds or echocardiograms) ensures that any changes are caught early and the treatment plan is adjusted as the patient grows [1][16].
Common questions in this guide
What causes Glycogen Storage Disease Type III?
How is low blood sugar managed in GSD III?
Why is a high-protein diet important for GSD III?
Do GSD III symptoms go away after puberty?
If I have GSD III, will my children inherit the disease?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific high-protein target (in grams per day) is appropriate for my current weight and age?
- 2.Should my partner undergo genetic testing to check if they are a carrier of the AGL mutation?
- 3.Which specialists do I need to see right away, and who will coordinate my overall care plan?
- 4.What are the immediate signs that my (or my child's) blood sugar is dropping too low, and what is our exact emergency protocol?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III.
Hijazi G, Paschall A, Young SP, et al.
Molecular genetics and metabolism reports 2021; (29()):100821 doi:10.1016/j.ymgmr.2021.100821.
PMID: 34820282 - 2
Continuous glucose monitoring (CGM) for effective glucose control in a pregnant woman living with type IIIa glycogenosis. A case report.
Bonnet JB, Fasolo M, Marty L, et al.
Clinical nutrition ESPEN 2024; (64()):519-524 doi:10.1016/j.clnesp.2024.11.010.
PMID: 39551345 - 3
Glycogen storage disease type III: a mixed-methods study to assess the burden of disease.
Evins A, Mayhew J, Cimms T, et al.
Therapeutic advances in endocrinology and metabolism 2024; (15()):20420188231224233 doi:10.1177/20420188231224233.
PMID: 38196773 - 4
Liver transplantation in patients with type IIIa glycogen storage disease, cirrhosis and hepatocellular carcinoma.
Iglesias Jorquera E, Tomás Pujante P, Ruiz García G, et al.
Revista espanola de enfermedades digestivas 2019; (111(2)):168-169 doi:10.17235/reed.2018.5856/2018.
PMID: 30318896 - 5
A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme.
Lim JA, Choi SJ, Gao F, et al.
Molecular therapy. Methods & clinical development 2020; (18()):240-249 doi:10.1016/j.omtm.2020.05.034.
PMID: 32637453 - 6
Molecular architecture and catalytic mechanism of human glycogen debranching enzyme.
Guan H, Chen H, Geng H, et al.
Nature communications 2025; (16(1)):5962 doi:10.1038/s41467-025-61077-6.
PMID: 40593796 - 7
[Analysis of two cases of glycogen storage disease type III due to compound heterozygous variants of AGL gene].
Zhang M, Wang C, Xie Z, et al.
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2021; (38(11)):1073-1076 doi:10.3760/cma.j.cn511374-20200803-00578.
PMID: 34729746 - 8
The biallelic novel pathogenic variants in AGL gene in a chinese patient with glycogen storage disease type III.
Wang J, Yu Y, Cai C, et al.
BMC pediatrics 2022; (22(1)):284 doi:10.1186/s12887-022-03252-y.
PMID: 35578201 - 9
Diurnal variability of glucose tetrasaccharide (Glc4) excretion in patients with glycogen storage disease type III.
Young SP, Khan A, Stefanescu E, et al.
JIMD reports 2021; (58(1)):37-43 doi:10.1002/jmd2.12181.
PMID: 33728245 - 10
Glycogen Storage Disease in Twins: When Two Lives Reflect One Silent Battle.
Shah RK, Khan SA, Devkota D, et al.
Clinical case reports 2026; (14(1)):e71889 doi:10.1002/ccr3.71889.
PMID: 41567525 - 11
Beneficial Effects of Modified Atkins Diet in Glycogen Storage Disease Type IIIa.
Olgac A, İnci A, Okur İ, et al.
Annals of nutrition & metabolism 2020; (76(4)):233-241 doi:10.1159/000509335.
PMID: 32712609 - 12
Nutritional management of glycogen storage disease type III: a case report and a critical appraisal of the literature.
Massimino E, Amoroso AP, Lupoli R, et al.
Frontiers in nutrition 2023; (10()):1178348 doi:10.3389/fnut.2023.1178348.
PMID: 37252245 - 13
Muscle Ultrasound in Patients with Glycogen Storage Disease Types I and III.
Verbeek RJ, Sentner CP, Smit GP, et al.
Ultrasound in medicine & biology 2016; (42(1)):133-42.
PMID: 26437929 - 14
Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring.
Halaby CA, Young SP, Austin S, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(12)):2686-2694 doi:10.1038/s41436-019-0561-7.
PMID: 31263214 - 15
Avascular necrosis as an uncommon manifestation in glycogen storage disease type III: diagnostic and therapeutic challenges.
Gorial FI, Awadh NI, Khunda SS, et al.
Oxford medical case reports 2025; (2025(8)):omaf145 doi:10.1093/omcr/omaf145.
PMID: 40843042 - 16
The Management and Clinical Outcomes of Pregnancy in a Female With Glycogen Storage Disease Type IIIA Caused by Rare Variant.
Puente-Ruiz N, Palaniappan S, Woodall A, et al.
JIMD reports 2025; (66(4)):e70030 doi:10.1002/jmd2.70030.
PMID: 40606795
This page provides educational information about GSD III (Cori/Forbes disease) and does not replace professional medical advice. Always consult your metabolic team before making changes to your diet or care plan.
Get notified when new evidence is published on Glycogen storage disease due to glycogen debranching enzyme deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.